首药控股(688197.SH)：2025年净亏损1.29亿元

Core Viewpoint - The company reported a significant increase in revenue but continued to incur losses, indicating challenges in achieving profitability despite growth in certain revenue streams [1] Financial Performance - The company achieved total revenue of 8.6676 million, representing a year-on-year increase of 119.88% [1] - The net profit attributable to the parent company was reported as -128.8342 million and -207.3189 million before and after deducting non-recurring gains and losses, respectively, indicating a narrowing of losses year-on-year [1] - As of the end of the reporting period, total assets amounted to 791.2337 million, with equity attributable to the parent company at 680.1789 million [1] Revenue Sources - The revenue during the reporting period primarily came from milestone payments for collaborative development projects and revenue sharing from the sales of drugs from collaborative projects [1] - The revenue generated was insufficient to cover the ongoing research and operational expenses, leading to a lack of profitability for the fiscal year 2025 [1]